Sex- and Age-Stratified Differences in Antidepressant Response to Intranasal Esketamine in Treatment-Resistant Depression: A Secondary Analysis of the REAL-ESK Study
Clinical Neuropsychopharmacology and Addiction June 25, 2026 Luca Persico, Giacomo D’andrea, Clara Cavallotto et al.
Background: Intranasal esketamine (ESK-NS) is an effective treatment for treatment-resistant depression (TRD), but whether antidepressant outcomes differ by sex and age remains insufficiently explored. Methods: This secondary analysis of the REAL-ESK study included 210 patients with TRD treated with ESK-NS in routine clinical practice and assessed at baseline (T0), one month (T1), and three...
DOI: 10.53941/cna.2026.100009 (opens in new tab)
Major depressive disorder
Discontinuation
Antidepressant
Depression economics
+7